DXCM : NASDAQ : Health Care
$78.68 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 1087700.0
06/22/17 - 4:00 PM ET

Financial Analysis


DEXCOM INC's gross profit margin for the first quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. DEXCOM INC has strong liquidity. Currently, the Quick Ratio is 1.56 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 20.15% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)142.3116.2
EBITDA ($mil)-36.7-15.8
EBIT ($mil)-40.4-19.2
Net Income ($mil)-41.7-19.2


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)181.1106.5
Total Assets ($mil)467.2299.4
Total Debt ($mil)81.71.7
Equity ($mil)277.8231.2


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin68.7367.56
EBITDA Margin-25.79-13.59
Operating Margin-28.39-16.52
Sales Turnover1.281.49
Return on Assets-18.85-21.34
Return on Equity-31.71-27.63
Debt Q1 FY17 Q1 FY16
Current Ratio1.923.55
Debt/Capital0.230.01
Interest Expense0.50.1
Interest Coverage-80.8-192.0


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)86.383.4
Div / share0.00.0
EPS-0.49-0.23
Book value / share3.222.77
Institutional Own % n/a n/a
Avg Daily Volume1052811.01288080.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 23.49 indicates a significant premium versus the S&P 500 average of 3.08 and a significant premium versus the industry average of 4.97. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, DEXCOM INC seems to be trading at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
DXCM NM Peers 43.59   DXCM 112.82 Peers 27.54

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

DXCM's P/E is negative making this valuation measure meaningless.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

DXCM is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
DXCM 581.62 Peers 24.69   DXCM NA Peers 0.97

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

DXCM's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
DXCM 23.49 Peers 4.97   DXCM -31.64 Peers 116.03

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

DXCM is trading at a significant premium to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, DXCM is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
DXCM 10.89 Peers 5.06   DXCM 34.57 Peers 14.46

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

DXCM is trading at a significant premium to its industry.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

DXCM has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades